Repeated Treatments With Botulinum Toxin Type A Produce Sustained Decreases in the Limitations Associated With Focal Upper-Limb Poststroke Spasticity for Caregivers and Patients

Archives of Physical Medicine and Rehabilitation

Volumn 89, Issue 5, 2008, Pages 799-806

  Elovic, Elie P ^a,f   Brashear, Allison ^b   Kaelin, Darryl ^c   Liu, Jingyu ^e   Millis, Scott R ^d   Barron, Richard ^e   Turkel, Catherine ^e  

^a KESSLER FOUNDATION   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c SHEPHERD CENTER   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ALLERGAN INC   (United States)

^f RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Botulinum toxin type A; Muscle spasticity; Quality of life; Rehabilitation; Stroke

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTHRALGIA; ARTICLE; CAREGIVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY ASSESSMENT SCALE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FEMALE; FUNCTIONAL DISEASE; HEADACHE; HUMAN; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE TONE; MUSCLE WEAKNESS; NORTH AMERICA; OPEN STUDY; PERIPHERAL EDEMA; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; SIDE EFFECT; SPASTICITY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VISUAL ANALOG SCALE;

ACTIVITIES OF DAILY LIVING; BOTULINUM TOXIN TYPE A; CAREGIVERS; DISABILITY EVALUATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MUSCLE SPASTICITY; MUSCLE TONUS; MUSCLE, SKELETAL; NEUROMUSCULAR AGENTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; STROKE; TREATMENT OUTCOME; UPPER EXTREMITY;

EID: 42649100971     PISSN: 00039993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apmr.2008.01.007     Document Type: Article

References (42)

1. Thom T., Haase N., Rosamond W., et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85-e151
2. Watkins C.L., Leathley M.J., Gregson J.M., Moore A.P., Smith T.L., and Sharma A.K. Prevalence of spasticity post stroke. Clin Rehabil 16 (2002) 515-522
3. Sommerfeld D.K., Eek E.U., Svensson A.K., Holmqvist L.W., and von Arbin M.H. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke 35 (2004) 134-139
4. Mayer N.H. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle Nerve Suppl 6 (1997) S1-S13
5. Mayer N.H., Esquenazi A., and Childers M.K. Common patterns of clinical motor dysfunction. Muscle Nerve Suppl 6 (1997) S21-S35
6. Cardoso E., Rodrigues B., Lucena R., Oliveira I.R., Pedreira G., and Melo A. Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis. Arq Neuropsiquiatr 63 (2005) 30-33
7. Mayo N.E., Wood-Dauphinee S., Cote R., Durcan L., and Carlton J. Activity, participation, and quality of life 6 months poststroke. Arch Phys Med Rehabil 83 (2002) 1035-1042
8. Sturm J.W., Donnan G.A., Dewey H.M., et al. Quality of life after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 35 (2004) 2340-2345
9. Elmstahl S., Malmberg B., and Annerstedt L. Caregiver's burden of patients 3 years after stroke assessed by a novel caregiver burden scale. Arch Phys Med Rehabil 77 (1996) 177-182
10. Anderson C.J., Linto J., and Stewart-Wynne E.G. A population-based assessment of the impact and burden of caregiving for long-term stroke survivors. Stroke 26 (1995) 843-849
11. Draper B.M., Poulos C.J., Cole A.M., Poulos R.G., and Ehrlich F. A comparison of caregivers for elderly stroke and dementia victims. J Am Geriatr Soc 40 (1992) 466-467
12. Gordon M.F., Brashear A., Elovic E., et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 63 (2004) 1971-1973
13. Bhakta B.B., Cozens J.A., Chamberlain M.A., and Bamford J.M. Impact of botulinum toxin type A on disability and career burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 69 (2000) 217-221
14. Kozma C.M., Burch S.P., Childers M.K., and Barron R. Effect of botulinum toxin type A on health-related quality of life in stroke patients with spasticity. [abstract]. Ann Neurol 50 Suppl 3 (2001) 78
15. Lagalla G., Danni M., Reiter F., Ceravolo M.G., and Provinciali L. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehabil 79 (2000) 377-384
16. Brashear A., Gordon M.F., Elovic E., et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 347 (2002) 395-400
17. Brashear A., Zafonte R., Corcoran M., et al. Inter- and intra-rater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil 83 (2002) 1349-1354
18. Bakheit A.M., Fedorova N.V., Skoromets A.A., Timerbaeva S.L., Bhakta B.B., and Coxon L. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 75 (2004) 1558-1561
19. Bakheit A.M., Thilmann A.F., Ward A.B., et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 10 (2000) 2402-2406
20. Bakheit A.M., Pittock S., Moore A.P., et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 8 (2001) 559-565
21. Simpson D.M., Alexander D.N., O'Brien C.F., et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 46 (1996) 1306-1310
22. Smith S.J., Ellis E., White S., and Moore A.P. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 14 (2000) 5-13
23. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 192 (1964) 540-542
24. Albright A.L., Barron W.B., Fasick M.P., Polinko P., and Janosky J. Continuous intrathecal baclofen infusion for spasticity of cerebral origin. JAMA 270 (1993) 2475-2477
25. van Straten A., de Haan R.J., Limburg M., Schuling J., Bossuyt P.M., and van den Bos G.A. A stroke-adapted 30-item version of the Sickness Impact Profile to assess quality of life (SA-SIP30). Stroke 28 (1997) 2155-2161
26. Brooks R. EuroQol: the current state of play. Health Policy 37 (1996) 53-72
27. Dolan P. Modeling valuations for EuroQol health states. Med Care 35 (1997) 1095-1108
28. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16 (1990) 199-208
29. Hatheway C.H., and Dang C. Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J., and Hallett M. (Eds). Therapy with botulinum toxin (1994), Marcel Dekker, New York 93-107
30. Hommel G. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika 75 (1988) 383-386
31. Brown E.G., Wood L., and Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 20 (1999) 109-117
32. Hanna P.A., Jankovic J., and Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry 66 (1999) 612-616
33. Langa K.M., Chernew M.E., Kabeto M.U., et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med 16 (2001) 770-778
34. Marra C.A., Esdaile J.M., Guh D., et al. A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care 42 (2004) 1125-1131
35. Nowels D., McGloin J., Westfall J.M., and Holcomb S. Validation of the EQ-5D quality of life instrument in patients after myocardial infarction. Qual Life Res 14 (2005) 95-105
36. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I: Conceptual framework and item selection. Med Care 30 (1992) 473-483
37. Gianino J.M., York M.M., Paice J.A., and Shott S. Quality of life: effect of reduced spasticity from intrathecal baclofen. J Neurosci Nurs 30 (1998) 47-54
38. Middel B., Kuipers-Upmeijer H., Bouma J., et al. Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 63 (1997) 204-209
39. Borodic G., Johnson E., Goodnough M., and Schantz E. Botulinum toxin therapy, immunologic resistance and problems with available materials. Neurology 46 (1996) 26-29
40. Botulinum toxin. Consens Statement 8 8 (1990) 1-20
41. Yablon S., Daggett S., and Brin M. Toxin neutralizing antibody formation with botulinum toxin type A (BoNTA) treatment in neuromuscular disorders. [abstract]. Neurology 64 Suppl 1 (2005) A72
42. Klein A.W. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg 29 (2003) 549-556